MGMT and glioblastoma: In accordance with clinical outcome, MGMT promoter-methylated GBM organoids showed higher sensitivity to TMZ in comparison to MGMT promoter-unmethylated organoids, an effect that is not always recapitulated in GBM cell lines (79).